A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Sponsor: Sinew Pharma Inc.
A PHASE2 clinical study on NASH - Nonalcoholic Steatohepatitis, this trial is ongoing. The trial is conducted by Sinew Pharma Inc. and has accumulated 13 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
13 versions recorded-
May 2025 — Present [monthly]
Unknown PHASE2
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2022 — Jun 2023 [monthly]
Not Yet Recruiting PHASE2
Status: Unknown Status → Not Yet Recruiting
▶ Show 8 earlier versions
-
Mar 2022 — Apr 2022 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sinew Pharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.